文献速递系统性红斑狼疮其他结缔组织病

Filgotinib或Lanraplenib治疗中重度皮肤型红斑狼疮的2期随机双盲安慰剂对照研究

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

这项2期随机双盲安慰剂对照探索性研究纳入47例活动性皮肤型红斑狼疮患者,评估Janus激酶1抑制剂filgotinib与脾酪氨酸激酶抑制剂lanraplenib治疗12周的安全性和疗效。主要终点(第12周CLASI-A评分较基线变化)未达到,但filgotinib组在部分亚组中显示较安慰剂组更大的数值改善,两种药物总体耐受性良好。

要点

  • 主要终点未达到:第12周CLASI-A评分变化filgotinib组为-8.7,安慰剂组为-5.5,差异无统计学意义
  • filgotinib组50%患者达到CLASI-A改善≥50%,安慰剂组为37.5%,lanraplenib组为31.3%
  • 两种药物不良事件多为轻中度,lanraplenib组报告2例严重不良事件,filgotinib组1例

核心结论

  • 主要终点未达到,但filgotinib在部分亚组中相对安慰剂显示数值上更大的治疗反应,lanraplenib和filgotinib总体耐受性良好。

研究设计与样本

  • 2期随机双盲安慰剂对照探索性概念验证研究,纳入47例活动性皮肤型红斑狼疮患者,随机接受lanraplenib 30 mg、filgotinib 200 mg或安慰剂每日一次治疗12周。
  • 第12周时安慰剂组患者按1:1重新随机接受lanraplenib或filgotinib治疗最多额外36周。

主要发现

  • 47例随机化患者中45例接受治疗(安慰剂组n=9,lanraplenib组n=19,filgotinib组n=17)。
  • 第12周CLASI-A评分较基线最小二乘均值变化:安慰剂组-5.5(标准误2.56),lanraplenib组-4.5(标准误1.91),filgotinib组-8.7(标准误1.85)。
  • 第12周CLASI-A评分改善≥5分的患者比例:安慰剂组50.0%,lanraplenib组56.3%,filgotinib组68.8%。
  • 第12周CLASI-A评分改善≥50%的患者比例:filgotinib组50%,安慰剂组37.5%,lanraplenib组31.3%。
  • 大多数不良事件为轻中度,lanraplenib组报告2例严重不良事件,filgotinib组报告1例。

关键数值与推荐

  • 主要终点为第12周CLASI-A评分较基线的变化,该终点未达到。
  • 第12周CLASI-A评分改善≥5分的比例在安慰剂组、lanraplenib组和filgotinib组分别为50.0%、56.3%和68.8%。
  • 第12周CLASI-A评分改善≥50%的比例在filgotinib组为50%,安慰剂组为37.5%,lanraplenib组为31.3%。

临床怎么用

  • 该研究未达到主要终点,filgotinib和lanraplenib暂不能作为皮肤型红斑狼疮的常规推荐治疗。
  • filgotinib在部分亚组中显示数值上更大的治疗反应,可能值得在特定人群中进行进一步研究。

局限性

  • 本研究为探索性2期概念验证研究,样本量小(45例接受治疗),各组样本量不均衡。
  • 主要终点未达到,亚组分析结果仅为数值差异,未报告统计学显著性检验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore the safety and efficacy of filgotinib (FIL), a Janus kinase 1 inhibitor, and lanraplenib (LANRA), a spleen kinase inhibitor, in cutaneous lupus erythematosus (CLE). METHODS: This was a phase 2, randomized, double-blind, placebo-controlled, exploratory, proof-of-concept study of LANRA (30 mg), FIL (200 mg) or placebo (PBO) once daily for 12 weeks in patients with active CLE. At week 12, PBO patients were rerandomized 1:1 to receive LANRA or FIL for up to 36 additional weeks. RESULTS: Of 47 randomized patients, 45 were treated (PBO, n = 9; LANRA, n = 19; FIL, n = 17). The primary endpoint [change from baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at week 12] was not met. The least squares mean CLASI-A score change from baseline was -5.5 (s.e. 2.56) with PBO, -4.5 (1.91) with LANRA and -8.7 (1.85) with FIL. Numerical differences between FIL and PBO were greater in select subgroups. A ≥5-point improvement in the CLASI-A score at week 12 was achieved by 50.0%, 56.3% and 68.8% in the PBO, LANRA and FIL arms, respectively. A numerically greater proportion of patients in the FIL arm (50%) also achieved ≥50% improvement in the CLASI-A score at week 12 (37.5% PBO, 31.3% LANRA). Most adverse events (AEs) were mild or moderate in severity. Two serious AEs were reported with LANRA and one with FIL. CONCLUSION: The primary endpoint was not met. Select subgroups displayed a numerically greater treatment response to FIL relative to PBO. LANRA and FIL were generally well tolerated. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT03134222.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Werth VP, Fleischmann R, Robern M, et al. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 2022. PMID: 34498056. doi:10.1093/rheumatology/keab685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。